Three-dimensional morphology scoring of hepatocellular carcinoma stratifies prognosis and immune infiltration. 2024

Xinxin Wang, and Can Yu, and Yu Sun, and Yixin Liu, and Shuli Tang, and Yige Sun, and Yang Zhou
Department of Radiology, Harbin Medical University Cancer Hospital, Harbin, China.

BACKGROUND The morphological attributes could serve as pivotal indicators precipitating early recurrence and dismal overall survival in hepatocellular carcinoma (HCC), and quantifying morphological features may better stratify the prognosis of HCC. OBJECTIVE To develop a radiomics approach based on 3D tumor morphology features for predicting the prognosis of HCC and identifying differentially expressed genes related to morphology to guide HCC treatment. METHODS Retrospective study of 357 HCC patients. Radiomic features were extracted from MRI tumor regions; 14 morphology-related features predicted early HCC recurrence and patient stratification via LASSO-Cox modeling. Overall survival (OS) and recurrence-free survival (RFS) were analyzed. RNA sequencing from the Cancer Imaging Archive (TCIA) examined drug sensitivity and stratified HCC using morphological immunity genes, validating recurrence and prognosis. RESULTS Patients were split into training (n = 225), test (n = 132), and 50 TCIA dataset cohorts. Two features (Maximum2DdiameterColumn, Sphericity) in Cox regression stratified patients into high/low-risk Morphological Radiological Score (Morph-RS) groups. Significant OS and RFS were seen across all sets. Differentially expressed genes focused on T cell receptor signaling; low-risk group had higher T cells (P = 0.039), B cells (P = 0.041), NK cells (P = 0.018). SN-38, GSK2126458 might treat high-risk morphology. Morphology-immune genes stratified HCC, showing significant RFS/OS differences. CONCLUSIONS Tumor Morph-RS effectively stratifies HCC patients' recurrence and prognosis. Limited immune infiltration seen in Morph-RS high-risk groups signifies the potential of employing tumor morphology as a potent visual biomarker for diagnosing and managing HCC.

UI MeSH Term Description Entries

Related Publications

Xinxin Wang, and Can Yu, and Yu Sun, and Yixin Liu, and Shuli Tang, and Yige Sun, and Yang Zhou
January 2021, Frontiers in medicine,
Xinxin Wang, and Can Yu, and Yu Sun, and Yixin Liu, and Shuli Tang, and Yige Sun, and Yang Zhou
January 2020, Journal of immunology research,
Xinxin Wang, and Can Yu, and Yu Sun, and Yixin Liu, and Shuli Tang, and Yige Sun, and Yang Zhou
February 2023, Pathology, research and practice,
Xinxin Wang, and Can Yu, and Yu Sun, and Yixin Liu, and Shuli Tang, and Yige Sun, and Yang Zhou
September 2020, World journal of gastroenterology,
Xinxin Wang, and Can Yu, and Yu Sun, and Yixin Liu, and Shuli Tang, and Yige Sun, and Yang Zhou
January 2021, Frontiers in oncology,
Xinxin Wang, and Can Yu, and Yu Sun, and Yixin Liu, and Shuli Tang, and Yige Sun, and Yang Zhou
September 2023, Discover. Oncology,
Xinxin Wang, and Can Yu, and Yu Sun, and Yixin Liu, and Shuli Tang, and Yige Sun, and Yang Zhou
September 2021, Bioscience reports,
Xinxin Wang, and Can Yu, and Yu Sun, and Yixin Liu, and Shuli Tang, and Yige Sun, and Yang Zhou
January 2022, Applied bionics and biomechanics,
Xinxin Wang, and Can Yu, and Yu Sun, and Yixin Liu, and Shuli Tang, and Yige Sun, and Yang Zhou
November 2021, BMC gastroenterology,
Xinxin Wang, and Can Yu, and Yu Sun, and Yixin Liu, and Shuli Tang, and Yige Sun, and Yang Zhou
January 2023, BMC bioinformatics,
Copied contents to your clipboard!